1. Inicio
  2. Publicaciones
  3. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Maurel, J
  • Sanchez-Cabus, S
  • Laquente, B
  • Gaba, L
  • Visa, L
  • Fabregat, J
  • Poves, I
  • Rosello, S
  • Martin-Richard, M
  • Rodriguez, J
  • Sabater, L
  • Conill, C
  • Cambray, M
  • Reig, A
  • Ayuso, JR
  • Valls, C
  • Ferrandez, A
  • Bombi, JA
  • Gines, A
  • Garcia-Albeniz, X
  • Fernandez-Cruz, L

Grupos

Abstract

BackgroundNeoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients.MethodsPatients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000mg/m(2)/week) plus daily erlotinib (ERL) (100mg/day). After re-staging, patients without progressive disease underwent 5 weeks of therapy with GEM (300mg/m(2)/week), ERL 100mg/day and concomitant radiotherapy (45Gy). Efficacy was assessed using tumor regression grade (TRG) and resection margin status. Using a single-arm Simon's design, considering the therapy not useful if R0<40% and useful if the R0>70% (alpha 5%, beta 10%), 24 patients needed to be recruited. This trial was registered at ClinicalTrials.gov, number NCT01389440.ResultsTwenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4-36.2) and 12.8 months (95% CI 8.6-17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p=0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p=0.009).ConclusionThe results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.

Datos de la publicación

ISSN/ISSNe:
0344-5704, 1432-0843

CANCER CHEMOTHERAPY AND PHARMACOLOGY  SPRINGER

Tipo:
Article
Páginas:
935-943
PubMed:
30225601
Factor de Impacto:
1,199 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Neoadjuant; Pancreatic; Adenocarcinoma

Campos de Estudio

Cita

Compartir